Nader Sanai, MD, Barrow Neurological Institute, Phoenix, AZ, discusses the results of a Phase 0 ‘trigger’ trial of pamiparib, a PARP1/2 inhibitor, in newly diagnosed and recurrent glioblastoma patients. The Phase 0 trial demonstrated pamiparib can effectively penetrate the CNS in both newly diagnosed and recurrent glioblastoma. Additionally, evidence of the molecular effect of pamiparip target inhibition was observed, as well as synergy with radiation. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.